Have a feature idea you'd love to see implemented?
Let us know!
CATX Perspective Therapeutics Inc
Price (delayed)
$3
Market cap
$202.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
-$19.41M
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Highlights
Perspective Therapeutics's gross profit has soared by 73% YoY and by 9% from the previous quarter
The revenue has increased by 2.5% since the previous quarter
Perspective Therapeutics's EPS has plunged by 54% YoY but it has increased by 10% from the previous quarter
The net income has plunged by 154% YoY and by 8% from the previous quarter
The company's quick ratio has shrunk by 66% QoQ
Key stats
What are the main financial stats of CATX
Market
Valuations
Earnings
Shares outstanding
67.59M
Market cap
$202.76M
Enterprise value
-$19.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
-$3.68M
EBIT
-$55.79M
EBITDA
-$53.78M
Free cash flow
-$40.59M
Per share
Balance sheet
Liquidity
EPS
-$1.49
Free cash flow per share
-$0.57
Book value per share
$4.87
Revenue per share
-$0.05
TBVPS
$4.49
Total assets
$391.15M
Total liabilities
$62.68M
Debt
$4.27M
Equity
$328.47M
Working capital
$242.03M
Debt to equity
0.01
Current ratio
9.6
Quick ratio
9.53
Net debt/EBITDA
4.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22.1%
Return on equity
-26.2%
Return on invested capital
-130.3%
Return on capital employed
-15.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CATX stock price
How has the Perspective Therapeutics stock price performed over time
Intraday
-51.38%
1 week
-66.37%
1 month
-76.38%
1 year
16.28%
YTD
-25.37%
QTD
-77.53%
Financial performance
How have Perspective Therapeutics's revenue and profit performed over time
Revenue
-$3.68M
Gross profit
$1.18M
Operating income
-$53.71M
Net income
-$63.79M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 154% YoY and by 8% from the previous quarter
The operating income has plunged by 75% YoY and by 20% from the previous quarter
Perspective Therapeutics's gross profit has soared by 73% YoY and by 9% from the previous quarter
The revenue has increased by 2.5% since the previous quarter
Growth
What is Perspective Therapeutics's growth rate over time
Valuation
What is Perspective Therapeutics stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Perspective Therapeutics's EPS has plunged by 54% YoY but it has increased by 10% from the previous quarter
CATX's P/B is 76% below its 5-year quarterly average of 2.6 and 73% below its last 4 quarters average of 2.3
CATX's equity is down by 3.7% since the previous quarter
The revenue has increased by 2.5% since the previous quarter
Efficiency
How efficient is Perspective Therapeutics business performance
CATX's ROIC is up by 44% YoY and by 27% QoQ
The ROA has increased by 18% from the previous quarter and by 8% YoY
The ROE has grown by 17% from the previous quarter
Dividends
What is CATX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CATX.
Financial health
How did Perspective Therapeutics financials performed over time
The company's quick ratio has shrunk by 66% QoQ
The current ratio has dropped by 65% since the previous quarter
The debt is 99% smaller than the equity
The debt to equity has shrunk by 67% YoY
The debt has increased by 29% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.